|
Jun 28
|
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
|
|
Jun 26
|
Edgewise Therapeutics Reports 'Positive' 3-Year Becker Data, Phase 2 Duchenne Muscular Dystrophy Findings for Sevasemten
|
|
Jun 26
|
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
|
|
Apr 15
|
Bristol Myers stumbles in bid to widen heart drug’s use
|
|
Apr 3
|
Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial
|
|
Apr 3
|
Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says
|
|
Apr 2
|
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
|
|
Apr 2
|
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'
|
|
Apr 2
|
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
|
|
Apr 2
|
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)
|
|
Mar 11
|
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
|
|
Mar 3
|
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
|
|
Feb 19
|
Should You Invest in Edgewise Therapeutics (EWTX)?
|
|
Oct 1
|
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
|
|
May 10
|
Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results
|
|
May 10
|
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
|
|
May 9
|
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 7
|
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
|
|
May 7
|
Edgewise Therapeutics doses first subject in HCM drug trial
|
|
May 6
|
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
|